Remove Immune Response Remove Medicine Remove Protein
article thumbnail

Feinstein Institutes researchers discover new protein for sepsis treatment

Pharmaceutical Technology

Researchers at the Feinstein Institutes for Medical Research have discovered a new protein that can be a potential therapeutic target for lethal sepsis. Led by Feinstein Institutes researcher Haichao Wang, the new study focuses on detecting protein mediators that might contribute to uncontrolled immune responses to lethal infections.

Protein 263
article thumbnail

EC grants approval for Sanofi-GSK’s Covid-19 booster

Pharmaceutical Technology

The European Commission (EC) has granted approval for Sanofi and GSK ’s monovalent, recombinant-protein-based, adjuvanted Covid-19 vaccine, VidPrevtyn Beta, as a booster in adults aged 18 years and above. It is indicated as a booster in people of this age group who were earlier inoculated with a Covid-19 vaccine.

Vaccine 246
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Lancet Respiratory Medicine: Clinical trial finds inhaled immune response protein increases odds of recovery for hospitalised COVID-19 patients

Scienmag

Inhaled delivery of a formulation of a key protein involved in the immune response – interferon beta-1a – to hospitalised COVID-19 patients in the UK reduced the odds that they would develop severe disease or die from SARS CoV-2 infection.

article thumbnail

Hipra’s Covid-19 booster gets EMA nod and enters an uncertain landscape

Pharmaceutical Technology

The European Medicines Agency (EMA) has recommended HIPRA’s Covid-19 vaccine , Bimervax, as a Covid-19 booster. Available to people ages 16 years and above who have been vaccinated with a Covid-19 mRNA vaccine, EMA’s Human Medicines Committee concluded the vaccine is ready for marketing authorization in the EU, on 30 March.

Vaccine 277
article thumbnail

Affordable protein-based SARS-CoV-2 vaccine, designed for older adults with waning immunity, shows promise

Scienmag

Despite great progress with SARS-CoV-2 vaccines, there is still a need to accelerate vaccination in low- and middle-income countries and a need for more effective vaccine strategies in older adults, who tend to have weaker immune responses to vaccination.

Protein 84
article thumbnail

Celltrion’s Avtozma Receives FDA Approval, Making it the Third Actemra Biosimilar to Hit the Market

XTalks

Avtozma is a recombinant humanized monoclonal antibody that acts as an interleukin 6 (IL-6) receptor antagonist that works by targeting specific inflammatory proteins to dampen immune responses. Avtozma was submitted for regulatory approval to the FDA in January 2024 and the European Medicines Agency (EMA) in February 2024.

article thumbnail

Grifols’ Innovation Strategy in the Plasma Medicine Space

XTalks

Plasma medicine is a critical and specialized field within healthcare, centering on the use of human plasma for the development and administration of life-saving treatments. Human plasma, the clear, liquid portion of blood, is composed of water, electrolytes, nutrients and crucial proteins such as antibodies, clotting factors and albumin.

Medicine 111